Exhar Formulations Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 20-12-2024
- Paid Up Capital ₹ 0.50 M
as on 20-12-2024
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.00 M
as on 20-12-2024
- Revenue 40.41%
(FY 2019)
- Profit 29.17%
(FY 2019)
- Ebitda 6.41%
(FY 2019)
- Net Worth 37.85%
(FY 2019)
- Total Assets 38.47%
(FY 2019)
About Exhar Formulations
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹3.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Anandam Sinha, Rajeev Kumar, Rakesh Sinha, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51511DL2007PTC162025
- Company No.
162025
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Exhar Formulations?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anandam Sinha  | Director | 13-Apr-2007 | Current |
| Rajeev Kumar | Director | 13-Apr-2007 | Current |
| Rakesh Sinha | Additional Director | 01-Jul-2009 | Current |
| Meeta Sinha | Additional Director | 01-Jul-2009 | Current |
| Binay Kumar | Additional Director | 01-Jul-2009 | Current |
| Rajiv Kumar | Additional Director | 01-Jul-2009 | Current |
Financial Performance of Exhar Formulations.
Exhar Formulations Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 40.41% increase. The company also saw a substantial improvement in profitability, with a 29.17% increase in profit. The company's net worth Soared by an impressive increase of 37.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Exhar Formulations?
In 2018, Exhar Formulations had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Excellent Nutraceuticals Private LimitedActive 14 years 9 monthsAnandam Sinha, Rajeev Kumar and 4 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Jul 2019 | ₹3.00 M | Satisfied |
How Many Employees Work at Exhar Formulations?
Exhar Formulations has a workforce of 9 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Exhar Formulations, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Exhar Formulations's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
